PepGen Shares Tumble After FDA Places Partial Hold on FREEDOM2-DM1 Trial
PepGen Inc. saw its stock fall 26% in after-hours trading after the U.S. Food and Drug Administration placed a partial clinical hold on the company’s FREEDOM2-DM1 Phase 2 trial. The hold centers on questions about previously submitted preclinical pharmacology and toxicology studies for PGN-EDODM1, the company’s candidate for myotonic dystrophy type…